Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors

Published:2020-10-23 Issue:10 Volume:3 Page:e2017675
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Bomze David¹²,Asher Nethanel³,Hasan Ali Omar²⁴,Flatz Lukas²⁴⁵,Azoulay Daniel⁶,Markel Gal³⁷,Meirson Tomer³⁸

Affiliation:

1. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

2. Institute for Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland

3. Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat-Gan, Israel

4. Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland

5. Department of Oncology, Kantonsspital St Gallen, St Gallen, Switzerland

6. Center for Liver Diseases, Sheba Medical Center, Ramat-Gan, Israel

7. Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

8. Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2772149/bomze_2020_oi_200639_1602793955.62411.pdf

Reference80 articles.

1. Combination cancer immunotherapies tailored to the tumour microenvironment.;Smyth;Nat Rev Clin Oncol,2016

2. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.;Usmani;Lancet Haematol,2019

3. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).;Schachter;Lancet,2017

4. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.;Motzer;Lancet Oncol,2019

5. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.;Eng;Lancet Oncol,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time;British Journal of Cancer;2024-05-06

2. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials;JNCI: Journal of the National Cancer Institute;2024-02-09

3. Online haemodiafiltration and all-cause mortality: how fragile are the results of the studies published so far?;Nephrology Dialysis Transplantation;2024-01-05

4. The Fragility of Landmark Randomized Controlled Trials in the Plastic Surgery Literature;Plastic and Reconstructive Surgery - Global Open;2024-01

5. Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study;BMJ;2023-12-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3